Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

sales@dingminpharma.com

86-311-67591193

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
HomeProductsAPIs And IntermediatesVemurafenib Intermediates
PRODUCT CATEGORIES

Vemurafenib Intermediates

(Total 4 Products)
Vemurafenib CAS 918504-65-1 1029872-54-5

Unit PriceUSD 5 / Gram

Min.Order Unit Price
1 Gram USD 5 / Gram

Supply Ability: As per order

API Vemurafenib Powder CAS No 918504-65-1 / 1029872-54-5 Product Name: Vemurafenib Other Name: Vemurafenib (PLX4032,RG7204) Cas No.: 918504-65-1 / 1029872-54-5 Molecular Formula: C23H18ClF2N3O3S Moculer Weight: 489.922 Appearence: White Crystalline...
Vemurafenib CAS 918504-65-1 1029872-54-5

Packaging: As required

Supply Ability: As per order

API Vemurafenib Powder CAS No 918504-65-1 / 1029872-54-5 Product Name: Vemurafenib Other Name: Vemurafenib (PLX4032,RG7204) Cas No.: 918504-65-1 / 1029872-54-5 Molecular Formula: C23H18ClF2N3O3S Moculer Weight: 489.922 Appearence: White Crystalline...
99% Vemurafenib Intermediate low price CAS 1103234-56-5

Packaging: As required

2,6-Difluoro-3-(propylsulfonamido)benzoic acid Vemurafenib intermediate CAS 1103234-56-5 Product name: 2,6-Difluoro-3-(propylsulfonaMido)benzoic acid Cas Number: 1103231-56-5 Moculer formula: C10H11F2NO4S Storage condition: keep in seal, cool and...
High quality 5-Bromo-7-azaindole CAS No 183208-35-7

Packaging: As required

Vemurafenib Intermediate 5-Bromo-7-azaindole CAS No 183208-35-7 Product name: 5-Bromo-7-azaindole Other name: 5-BROMO-1H-PYRROLO[2,3-B]PYRIDINE Cas No.: 183208-35-7 EINECS No:629-247-8 Molecular Formula: C7H5BrN2 Moculer weight: 197.03 Appearence:...

China Vemurafenib Intermediates Suppliers

Vemurafenib is a BRAF kinase inhibitor that inhibits the activity of mutant BRAF V600E, as well as CRAF, ARAF and wild-type BRAF kinases. Vemurafenib is a competitive small molecule inhibitor of serine-threonine kinase targeting the ATP-binding domain of mutant BRAF. In cells without BRAF mutation, Vemurafenib can enhance activation of downstream MEK by RAF homo- or heterodimers, which is due to the non-reactivity of BRAF-CRAF heterodimers and CRAF-CRAF homodimers. Caused by transactivation of drug binding partners.
Home > Products > APIs And Intermediates > Vemurafenib Intermediates

New Products

Related Products List

Home

Product

Phone

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send